Scleroderma Clinical Trial
Official title:
Non-invasive Oxygen-Ozone Therapy in the Treatment of Digital Ulcers in Egyptian Patients With Systemic Sclerosis
Digital ulcers (DUs) in scleroderma result from recurrent Raynaud's phenomenon (RP) and microtrauma with high impact on quality of life, management of DUs is a great challenge for clinicians. Medical use of ozone (triatomic oxygen) was initiated in the 19th century. Ozone has multiple therapeutic effects in wound healing due to the property of releasing nascent oxygen, which has been shown to stimulate antioxidant enzymes.
Digital ulcers (DUs) in scleroderma result from recurrent Raynaud's phenomenon (RP) and microtrauma with high impact on quality of life, management of DUs is a great challenge for clinicians. Medical use of ozone (triatomic oxygen) was initiated in the 19th century. Ozone has multiple therapeutic effects in wound healing due to the property of releasing nascent oxygen, which has been shown to stimulate antioxidant enzymes, we aim to assess the effects of ozone therapy on the healing in Scleroderma DUs and the expressions of vascular endothelial growth factor (VEGF), and endothelin-1 type A receptor (ETAR) and angiotensin II type 1 receptor (AT1R) autoantibodies level in the wounds after treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02798055 -
Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis
|
||
| Completed |
NCT01959815 -
Novel Screening Strategies for Scleroderma PAH
|
||
| Completed |
NCT03274076 -
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
|
Phase 1/Phase 2 | |
| Completed |
NCT02915835 -
Riociguat in Scleroderma Associated Digital Ulcers
|
Phase 2 | |
| Active, not recruiting |
NCT01895244 -
Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis
|
Phase 2 | |
| Completed |
NCT00883129 -
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
|
Phase 2 | |
| Completed |
NCT00930683 -
A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma
|
Phase 1 | |
| Completed |
NCT00074568 -
Scleroderma Registry
|
||
| Recruiting |
NCT04797286 -
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
|
Phase 2 | |
| Completed |
NCT03222492 -
Brentuximab Vedotin for Systemic Sclerosis
|
Phase 1/Phase 2 | |
| Completed |
NCT03207997 -
MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients
|
N/A | |
| Recruiting |
NCT04464434 -
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 4 | |
| Recruiting |
NCT04246528 -
SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)
|
N/A | |
| Completed |
NCT05080738 -
Upper Extremity Home Exercises in Patients With Scleroderma
|
N/A | |
| Recruiting |
NCT03726398 -
CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05085444 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
|
Early Phase 1 | |
| Completed |
NCT02062125 -
Calcinosis in a Single-Center Scleroderma Population
|
||
| Completed |
NCT04588714 -
Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention
|
N/A | |
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Completed |
NCT02835196 -
Optical Elastography of Systemic Sclerosis Skin
|